Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.45 |
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | CDK8 | P49336 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22044571 | 0.86 | ROCK2 (0.46) | ROCK2ROCK1ATMMAPK1MAPK14 | |
| SCHEMBL22044123 | 0.85 | ROCK2 (0.53) | ROCK2ROCK1DYRK1BCDC7CDK8 | |
| SCHEMBL22044118 | 0.84 | CAMKK2 (0.55) | ROCK2ROCK1DYRK1BCDC7CDK8 | |
| SCHEMBL22043985 | 0.84 | MAPK1 (0.48) | ROCK2ROCK1ATMMAPK1 | |
| SCHEMBL22044046 | 0.84 | AKT1 (0.53) | ROCK2ROCK1DYRK1BCDC7CDK8 | |
| SCHEMBL22044061 | 0.83 | ROCK2 (0.47) | ROCK2ROCK1DYRK1BCDC7CDK8 | |
| SCHEMBL22043993 | 0.79 | ROCK2 (0.54) | ROCK2ROCK1CDC7DYRK1ACLK4 | |
| SCHEMBL4476811 | 0.78 | ROCK1 (0.58) | ROCK2ROCK1CLK4 | |
| SCHEMBL22044531 | 0.76 | MAPK1 (0.55) | ROCK2ROCK1ATMMAPK1 | |
| SCHEMBL13887911 | 0.76 | CYP3A4 (0.61) | ROCK2ROCK1DYRK1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | ROCK2 1660/4885ROCK1 1252/4885DYRK1B 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.